BACKGROUND The Svelte (New Providence, NJ) sirolimus-eluting coronary stent utilizing a bioresorbable amino acid-based (PEA) drug carrier is a novel stent-on-a-wire Integrated Delivery System (IDS) consisting of a low-compliant balloon with balloon control bands (BCBs) affixed to a 0.014" integrated steerable wire with shapeable tip. The IDS is low-profile and specifically designed for use with the transradial approach, 'slender' PCI and direct stenting. The DIRECT I first-in-human study was designed to evaluate the feasibility of the Svelte drug-eluting stent IDS.
METHODS Thirty patients with symptomatic ischemic heart disease and a single de novo native coronary lesion suitable for percutaneous coronary intervention were prospectively enrolled at 4 New Zealand sites. Lesion length had to be <23 mm and the vessel reference diameter 2.5-3.5 mm. The primary safety endpoint was 6-month target vessel failure (TVF), defined as the composite of death, target vessel MI or clinically-driven target vessel revascularization (TLR). The primary efficacy endpoint was 6-month angiographic in-stent late lumen loss (LLL). All patients were scheduled to receive angiographic and IVUS follow-up at baseline and 6-months, with 15 patients additionally undergoing OCT analysis at the same time points. All angiographic and clinical data were reviewed and adjudicated by an independent core lab and DSMB at all reported time points.
RESULTS Twenty-nine of 30 enrolled patients completed 6-month follow-up. Angiographic in-stent LLL was 0.22þ0.27 mm at 6months. Other 6-month follow-up included IVUS assessed neointimal volume of 3.3þ 4.4mm3 and volume obstruction of 2.7þ4.5%. OCT revealed 98þ4% strut coverage at a depth of 0.12þ0.06 mm. Through 36-month followup, no patient has experienced stent thrombosis, MACE or TVF. RESULTS After propensity score matching, the baseline clinical characteristics were similar in Absorb BVS and EES groups. As shown in Figure 1 and BACKGROUND As progressively more elderly and comorbid patients are being considered for revascularization the need for one year of dual anti-platelets becomes of increasing concern. SYNERGYÔ Everolimus-eluting platinum chromium coronary stents allow for early cessation of dual antiplatelet therapy (DAPT) due to complete polymer absorption and drug elution by three months. The aim of this study was to retrospectively assess those in our unit who have underwent PCI with a SYNERGYÔ stent to look for adverse outcomes postdiscontinuation of DAPT.
METHODS All patients in our unit who underwent clinically indicated PCI with a SYNERGYÔ stent from August 2013-December 2014 were retrospectively analyzed. Patients who have been enrolled in multicenter trails during the same time period are not included in this cohort. Baseline and procedural characteristics were recorded. Follow-up was by review of medical records or telephone contact for post-procedural complications or adverse events.
RESULTS
In total 100 patients underwent PCI with a SYNERGYÔ during the one-year study period. The mean age was 72.3 years (AE10.0; range 41-92 years), 37% of the cohort was defined as elderly (age >75 years) and 8% defined as very elderly (age >85 years). Mean EuroSCORE was 11.37 (AE11.13, range 0.88-70.23). The indication for SYNERGYÔ stent use was as follows; frail or elderly (16%), concurrent anticoagulation (28%) need for a non-cardiac procedure (10%), increased bleeding risk (31%), or other (15%). NSTEMI/STEMI was the presenting complaint in 32% of patients. The coronary disease was complex. Left main stem was involved in (13%), multi-vessel disease (36%), bifurcation disease requiring side-branch stenting (9%), and 37% required CTO intervention. Mean Syntax score was 22.7 (AE12.1, range 6-53). The mean stent length/ patient was 75.3mm (AE41.5) with 1.44 AE0.64) lesions treated and 2.67 (AE1.33) stents implanted per patient. DAPT discontinuation by 3 months has occurred in 77% to date. Despite the patient and lesion complexity, there were no thrombotic events after discontinuation of anti-platelets (acute, sub-acute or late stent thrombosis). Eleven patients were able to undergo non-cardiac surgery after three months DAPT. By a minimum of six months (median follow up time per patient 341 days) follow up four patients died from non-cardiac causes (one from cancer, one sepsis and multi-organ failure, one ruptured abdominal aortic aneurysm and one vascular complication post-TAVI). There were two target vessel revascularizations (TVR) and one patient underwent CABG but no incidence of stent thrombosis by the same time-point.
